

Edwards Lifesciences (EW)

Presented by Jane Nelson,
Director, Rocky Mountain Chapter

[1]

Disclaimer:

- The stock we are studying tonight is used for educational purposes only. Small Talk was started in order to show members how to evaluate small/ medium sized companies since the research and evaluation is more difficult. This company is tonight's example.

[2]

Edwards Lifesciences

Business summary:

Baxter Int'l. spin off in 2000

Designs, manufactures & markets range of medical devices & equipment for advanced stages of heart disease.

Key products: tissue heart valves, surgical clips, catheters, & monitors

(3)

Product Lines

Surgical Heart Valve Therapy: 36%

-tissue heart valves & repair

Transcatheter Heart Valve Therapy:


41% -used SHVT to optimize this therapy

Clinical Care: 24%

-hemodynamic monitoring systems

(4)

Examples of Products



[5]

Surgical Heart Valve Therapy



**Carpentier-Edwards PERIMOUNT
aortic valve**

[6]

Transcatheter Aortic Valve Replacement



[7]



[8]

Medical Supply (Invasive) Ind.

- Defined by need to surgically puncture body to provide therapeutic relief.
- Overseas macroeconomic weakness & political instability
- Uneven recovery at home
 - Slow hospital admissions
 - High rate of deferrals

[9]

- 2.3% ACA medical device tax
- Cardiovascular market has stabilized
- Diversification into related fields
- Cost control
- Consolidation
- Supreme Court decision set

[10]

Strengths of EW

- Industry pioneer, #1 in heart valves, leader in hemodynamic monitoring
- High barrier to enter field
- Strong brand and relationships
 - Proctoring/training
 - Royalty/licensing arrangements
 - Website publishes MDs names

[11]

Robust R&D pipeline

Strong fundamentals

Aging population/ deferrals

MDT settlement/royalties

3/15/15-PARTNER Trial-SAPIEN

3/15/15-PARTNER Trial-SAPIEN 3

Transcatheter mitral valve leaders

[12]

Weaknesses of EW

High SAPIEN price > payers back off
Latest devices may not be OK'd here
Competition with competitors over
minimally invasive technologies.
Little success with transcatheter
mitral valves.
More competition expected

(13)

Opportunities for EW

Efficiency & higher margin products.
Market stabilization in cardio field.
R&D by all will expand field.
Foreign and emerging market
expansion.
Newer low cost plant in Singapore.

(14)

Threats to EW

- TAVs become interchangeable as stents, = business loss.
- 2.3% ACA medical device tax.
- Difficult currency translations.
- Studies show not worthwhile.
- Competition in medical tools.

• Small Talk, March 24, 2015

{ 15 }